Advertisement

International Journal of Hematology

, Volume 96, Issue 5, pp 611–616 | Cite as

The JAK2 46/1 haplotype is a risk factor for myeloproliferative neoplasms in Chinese patients

  • Xinju Zhang
  • Tingting Hu
  • Zhiyuan Wu
  • Zhihua Kang
  • Weiwei Liu
  • Ming Guan
Original Article

Abstract

The presence of JAK2 V617F is associated with an inherited JAK2 46/1 haplotype, a risk factor for myeloproliferative neoplasms (MPN) in Caucasian populations. Whether the JAK2 46/1 haplotype is also a risk factor in the Chinese population is unknown. We assessed for the JAK2 46/1 haplotype and JAK2 V617F mutation in 225 MPN patients and 226 controls using a tagged SNP rs12340895. The allele frequencies of the JAK2 46/1 haplotype were distinct among different subtypes of MPN patients. The allele frequency was significantly higher in polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) than that in controls, with PV patients having the highest allele frequency (0.58, P = 6.00E−15). The distribution of rs12340895 genotypes in the JAK2 V617F mutated MPN patients was significantly different from that in controls (P = 1.67E−15). The percentage of GG genotype in controls was 2.2 %, but 31.0 % in JAK2 V617F-positive MPN patients. All the PV, ET, and PMF patients with the GG genotype also exhibited the V617F mutation. Compared to that of controls, the difference in genotype distribution in PV patients was the most significant (P = 4.83E−21), followed by ET (P = 2.07E−05) and PMF (P = 1.99E−04). Our results suggest that the JAK2 46/1 haplotype is a risk factor for MPN in the Chinese population, and patients with GG genotype in rs12340895 locus are susceptible to JAK2 V617F mutation.

Keywords

JAK2 V617F SNP Myeloproliferative neoplasms 

Notes

Acknowledgments

This study was supported by a grant from the National Clinical Key Subject, and two grants from the Shanghai Science and Technology Commission (Grant No. 11JC1401800 and No. 10411950200) and Scientific Research Foundation for New teacher of Fudan University (JJF151002).

Conflict of interest

The authors declare that they have no conflict of interests.

References

  1. 1.
    Abdel-Wahab O. Genetics of the myeloproliferative neoplasms. Curr Opin Hematol. 2011;18(2):117–23.PubMedCrossRefGoogle Scholar
  2. 2.
    Ohyashiki JH, Yoneta M, Hisatomi H, Iwabuchi T, Umezu T, Ohyashiki K. The C allele of JAK2 rs4495487 is an additional candidate locus that contributes to myeloproliferative neoplasm predisposition in the Japanese population. BMC Med Genet. 2012;13:6.PubMedCrossRefGoogle Scholar
  3. 3.
    Olcaydu D, Harutyunyan A, Jager R, Berg T, Gisslinger B, Pabinger I, et al. A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nat Genet. 2009;41(4):450–4.PubMedCrossRefGoogle Scholar
  4. 4.
    James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434(7037):1144–8.PubMedCrossRefGoogle Scholar
  5. 5.
    Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7(4):387–97.PubMedCrossRefGoogle Scholar
  6. 6.
    Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365(9464):1054–61.PubMedGoogle Scholar
  7. 7.
    Tefferi A, Vainchenker W. Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. J Clin Oncol. 2011;29(5):573–82.PubMedCrossRefGoogle Scholar
  8. 8.
    Landgren O, Goldin LR, Kristinsson SY, Helgadottir EA, Samuelsson J, Bjorkholm M. Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden. Blood. 2008;112(6):2199–204.PubMedCrossRefGoogle Scholar
  9. 9.
    Kilpivaara O, Mukherjee S, Schram AM, Wadleigh M, Mullally A, Ebert BL, et al. A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. Nat Genet. 2009;41(4):455–9.PubMedCrossRefGoogle Scholar
  10. 10.
    Jones AV, Chase A, Silver RT, Oscier D, Zoi K, Wang YL, et al. JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat Genet. 2009;41(4):446–9.PubMedCrossRefGoogle Scholar
  11. 11.
    Wu Z, Yuan H, Zhang X, Liu W, Xu J, Zhang W, et al. Development and inter-laboratory validation of unlabeled probe melting curve analysis for detection of JAK2 V617F mutation in polycythemia vera. PLoS ONE. 2011;6(10):e26534.PubMedCrossRefGoogle Scholar
  12. 12.
    Vossen RH, van Duijn M, Daha MR, den Dunnen JT, Roos A. High-throughput genotyping of mannose-binding lectin variants using high-resolution DNA-melting analysis. Hum Mutat. 2010;31(4):E1286–93.PubMedCrossRefGoogle Scholar
  13. 13.
    Liu SM, Xu FX, Shen F, Xie Y. Rapid genotyping of APOA5 -1131T>C polymorphism using high resolution melting analysis with unlabeled probes. Gene. 2012;498(2):276–9.Google Scholar
  14. 14.
    Bole-Feysot C, Goffin V, Edery M, Binart N, Kelly PA. Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. Endocr Rev. 1998;19(3):225–68.PubMedCrossRefGoogle Scholar
  15. 15.
    Reddy MM, Deshpande A, Sattler M. Targeting JAK2 in the therapy of myeloproliferative neoplasms. Expert Opin Ther Targets. 2012;16(3):313–24.PubMedCrossRefGoogle Scholar
  16. 16.
    Ghoreschi K, Laurence A, O’Shea JJ. Janus kinases in immune cell signaling. Immunol Rev. 2009;228(1):273–87.PubMedCrossRefGoogle Scholar
  17. 17.
    Pardanani A, Lasho TL, Finke CM, Gangat N, Wolanskyj AP, Hanson CA, et al. The JAK2 46/1 haplotype confers susceptibility to essential thrombocythemia regardless of JAK2V617F mutational status-clinical correlates in a study of 226 consecutive patients. Leukemia. 2010;24(1):110–4.PubMedCrossRefGoogle Scholar
  18. 18.
    Hermouet S, Vilaine M. The JAK2 46/1 haplotype: a marker of inappropriate myelomonocytic response to cytokine stimulation, leading to increased risk of inflammation, myeloid neoplasm, and impaired defense against infection? Haematologica. 2011;96(11):1575–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Zhang X, Gu X, Liu S, Ma W, Guan M. Detection of JAK2 V617F mutation by real-time PCR. Clin J Lab Med (Chinese). 2009;32(5):583–6.Google Scholar
  20. 20.
    Alvarez-Larran A, Angona A, Martinez-Aviles L, Bellosillo B, Besses C. Influence of JAK2 46/1 haplotype in the natural evolution of JAK2V617F allele burden in patients with myeloproliferative neoplasms. Leuk Res. 2012;36(3):324–6.PubMedCrossRefGoogle Scholar
  21. 21.
    Vannucchi AM, Antonioli E, Guglielmelli P, Longo G, Pancrazzi A, Ponziani V, et al. Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. Leukemia. 2007;21(9):1952–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Andrikovics H, Nahajevszky S, Koszarska M, Meggyesi N, Bors A, Halm G, et al. JAK2 46/1 haplotype analysis in myeloproliferative neoplasms and acute myeloid leukemia. Leukemia. 2010;24(10):1809–13.PubMedCrossRefGoogle Scholar
  23. 23.
    Guglielmelli P, Biamonte F, Spolverini A, Pieri L, Isgro A, Antonioli E, et al. Frequency and clinical correlates of JAK2 46/1 (GGCC) haplotype in primary myelofibrosis. Leukemia. 2010;24(8):1533–7.PubMedCrossRefGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2012

Authors and Affiliations

  1. 1.Department of Central Laboratory, Huashan HospitalShanghai Medical College, Fudan UniversityShanghaiPeople’s Republic of China
  2. 2.Department of Laboratory Medicine, Huashan HospitalShanghai Medical College, Fudan UniversityShanghaiPeople’s Republic of China

Personalised recommendations